These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4053412)

  • 1. The influence of oestrogens on the sensitivity of PRL, TSH and LH to the inhibitory actions of dopamine in hyperprolactinaemic patients.
    Valcavi R; Harris PE; Foord SM; Dieguez C; Evans PJ; Peters JR; Hall R; Scanlon MF
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):139-46. PubMed ID: 4053412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
    Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interrelationships between prolactin and thyrotrophin secretion following dopaminergic blockage in patients with mild hyperprolactinaemia without any demonstrable pituitary tumour.
    Spitz IM; Haas M; Trestian S; Zylber-Haran E; Shilo S
    Clin Endocrinol (Oxf); 1983 Sep; 19(3):285-94. PubMed ID: 6414745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible thyrotrophs insensitivity to dopamine in hyperprolactinaemic amenorrhoeic patients.
    Nyboe Andersen A; Hagen C; Boesgaard S; Eldrup E; Djursing H
    Horm Metab Res; 1989 Jun; 21(6):328-30. PubMed ID: 2777190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women.
    Giusti M; Lomeo A; Torre R; Sghedoni D; Mazzocchi G; Durante R; Giordano G
    Clin Endocrinol (Oxf); 1989 Mar; 30(3):315-21. PubMed ID: 2574083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catecholamines and pituitary function. IV. Effects of low-dose dopamine infusion and long-term bromocriptine treatment on the abnormal thyrotroph (TSH) dynamics in patients with pathological hyperprolactinaemia.
    Nicoletti I; Filipponi P; Fedeli L; Ambrosi F; Giammartino C; Spinozzi F; Santeusanio F
    Acta Endocrinol (Copenh); 1986 Feb; 111(2):154-61. PubMed ID: 3082094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catecholamines and pituitary function. VII: Effects of acute and chronic dopamine-receptor blockade on pituitary response to TRH-GNRH in normal women and in patients with hyperprolactinemic amenorrhea.
    Giammartino C; Ambrosi F; Pelicci G; Pagliacci MC; Fedeli L; Nicoletti I
    Horm Metab Res; 1988 Jan; 20(1):44-8. PubMed ID: 3131222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of changes in serum estradiol and progesterone during the menstrual cycle to the thyrotropin and prolactin responses to thyrotropin-releasing hormone.
    Sawin CT; Hershman JM; Boyd AE; Longcope C; Bacharach P
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1296-302. PubMed ID: 122427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade.
    Ghigo E; Goffi S; Molinatti GM; Camanni F; Massara F
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):155-60. PubMed ID: 3931942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.
    Nicoletti I; Filipponi P; Fedeli L; Sfrappini M; Gregorini G; Ambrosi F; Santeusanio F
    Horm Res; 1984; 20(3):202-12. PubMed ID: 6436160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of altered dopaminergic modulation of Prl, LH, FSH, GH and TSH secretion during chronic partial dopamine receptor blockade in normal women.
    Hagen C; Andersen AN; Djursing H
    Acta Endocrinol (Copenh); 1984 May; 106(1):1-7. PubMed ID: 6428112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of naloxone infusion on plasma levels of LH, FSH, and in addition TSH and prolactin in males, before and after oestrogen or anti-oestrogen treatment.
    van Bergeijk L; Gooren LJ; van Kessel H; Sassen AM
    Horm Metab Res; 1986 Sep; 18(9):611-5. PubMed ID: 3096859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic control of gonadotrophin secretion in normal women and in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Clin Endocrinol (Oxf); 1984 Jan; 20(1):53-63. PubMed ID: 6420095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of gonadotropin and prolactin release by dopamine: effect of endogenous estradiol levels.
    Judd SJ; Rakoff JS; Yen SS
    J Clin Endocrinol Metab; 1978 Sep; 47(3):494-8. PubMed ID: 122409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.
    Scanlon MF; Rodriguez-Arnao MD; McGregor AM; Weightman D; Lewis M; Cook DB; Gomez-Pan A; Hall R
    Clin Endocrinol (Oxf); 1981 Feb; 14(2):133-43. PubMed ID: 6790201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of dopamine on the altered release of prolactin, luteinizing hormone, and follicle-stimulating hormone induced by interleukin-2 in vitro.
    Karanth S; Marubayashi U; McCann SM
    Neuroendocrinology; 1992 Dec; 56(6):871-80. PubMed ID: 1369597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
    Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
    Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fenoldopam, a dopamine D-1 receptor agonist, on pituitary, gonadal and thyroid hormone secretion.
    Boesgaard S; Hagen C; Andersen AN; Eldrup E; Lange P
    Clin Endocrinol (Oxf); 1989 Mar; 30(3):231-9. PubMed ID: 2574081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced hypothalamic dopaminergic inhibition of LH, TSH and GH release in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Acta Endocrinol (Copenh); 1985 Mar; 108(3):289-96. PubMed ID: 3984660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.